News Ozanimod Reduces Multiple Sclerosis Relapse Rate, Phase 3 Trial Shows Ozanimod Reduces Multiple Sclerosis Relapse Rate, Phase 3 Trial Shows by Patricia Silva, PhD | February 20, 2017 Share this article: Share article via email Copy article link A Phase 3 clinical trial evaluating the safety and effectiveness of ozanimod (RPC-1063) in patients withĀ relapsing multiple sclerosis (RMS)Ā shows treatment reduced the disease’s annualized relapse rate (ARR), researchers reported. The Phase 3 SUNBEAM trial (NCT02294058)Ā testedĀ ozanimod, anĀ oral, selective sphingosine 1-phosphate 1 (S1PR1) and 5 (S1PR5) receptor modulator designed to treat immune-inflammatory conditions such as RMS. Lowering ARR was this study’s primary goal for the treatment, being developed byĀ Ā Celgene Corporation. Those with RMS can experience relapses ā also called flare-ups or exacerbationsĀ ā that worsenĀ their neurologic function. Relapses are usually followed by partial or complete recovery periods, called remissions, during which symptoms cease or partially improve, and the disease appears to stabilize. Ozanimod works by binding toĀ S1PR1 and S1PR5 receptors. The binding inhibits certain lymphocytes, or immune cells, from migrating to sites of inflammation. This reduces circulating T- and B-lymphocytes, stabilizing immune function. The SUNBEAM study enrolledĀ 1,346 RMS patients at 152 sites in 20 countries. Researchers compared the safety, effectiveness and tolerability of two oral doses of ozanimod ā 0.5 mg and 1 mg ā with an intramuscular injection of interferon beta-1a (Avonex) once a week for at least 12 months. Both doses of ozanimod were much more effective (showed statistically significant and clinically meaningful improvement) compared to Avonex in achieving the trial’s primary objective ā a lower relapse rate ā and the secondary endpoint of fewer brain MRI lesions over 12 months, data showed. Ozanimod’s overall safety and tolerability profile was consistent with that reported in previous studies, such as the Phase 2-3Ā RADIANCE (NCT02047734) trial in MS patients, and a Phase 2 study in people with ulcerative colitis, the company also reported. āThese data add to the growing body of evidence supporting the use of ozanimod as a disease-modifying therapy for relapsing forms of multiple sclerosis,ā Bruce Cree, associate professor of neurology at the University of California, San Francisco, said in a press release. āWe look forward to the continued study of ozanimod as well as presentation of the full results of the phase III trial at an upcoming international scientific meeting.ā A long-term and open-label (meaning no placebo group) extension study (NCT02576717) Ā involving some 2,350 RMS patients from previous trials is now underway. This safety and efficacy study is expected to include in June 2020. Researchers will also, under an agreement with theĀ U.S. Food and Drug Administration (FDA), analyze the time it takes for patients’ condition to progress to disability. Their measuring stick will be a deterioration of 1 or more points in aĀ patient’s Expanded Disability Status Scale (EDSS) score, confirmed after three and six months. This analysis will use data from both the Phase 3Ā SUNBEAM and RADIANCEĀ trials. āPeople living with multiple sclerosis need additional therapies, and we are pleased that oral ozanimod showed meaningful improvements across primary and measured secondary endpoints in this study,ā said Scott Smith, president of Celgene Inflammation and Immunology. āWe look forward to data from the confirmatory phase III RADIANCE trial in the second quarter as we advance toward planned regulatory submissions by year-end.ā Print This Page About the Author Patricia Silva, PhD PatrĆcia holds a PhD in medical microbiology and infectious diseases from the Leiden University Medical Center, Netherlands, and completed a postdoctoral research fellowship at the Instituto de Medicina Molecular, Lisbon, Portugal. Her work in academia was mainly focused on molecular biology and the genetic traits of infectious agents such as viruses and parasites. PatrĆcia earned several travel awards to present her work at international scientific meetings. She is a published author of several peer-reviewed science articles. Tags annualized relapse rate, disability, MRI lesions, Ozanimod, RADIANCE, relapsing MS, SUNBEAM
April 24, 2024 News by Lindsey Shapiro, PhD Autoantibodies seen in blood years before MS diagnosis: Study
April 23, 2024 News by Mary Chapman Itās year 10 for MSAAās upcoming Improving Lives Benefit for MS
April 23, 2024 News by Margarida Maia, PhD AAN 2024: Subcutaneous Ocrevus led to nearly no relapses after year